First generic copy of Roche’s Tamiflu hits US market
pharmafile | December 12, 2016 | News story | Sales and Marketing | Alvogen, Roche, Tamiflu
Drugmaker Alvogen has released the first generic version of Roche’s flu medication Tamiflu (oseltamivir) in the US, where it expects to save the healthcare system as much as $500 million.
Developed in cooperation with India-based Natco Pharma, the drug is available in three strengths: 30mg, 45mg and 75mg.
“The launch of oseltamivir phosphate is great news for US patients, who will finally have access to a more affordable alternative to Tamiflu,” commented Robert Wessman, chairman and CEO of Alvogen. “It is also an important milestone for our U.S. business. The launch demonstrates our ability to move quickly and we are proud to partner with Natco to bring this product to market.”
While it accounts for a relatively small portion of Roche’s overall revenue, Tamiflu managed to earn $3 billion in the wake of the H1N1 swine flu outbreak of 2009.
According to IMS Health, Alvogen’s drug portfolio has reported current brand sales in excess of $25 billion.
Matt Fellows
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …